tweet at 7:00am: Moderna: Vaccine Efficacy Against COVID-19 Was 94.1%; Vaccine Efficacy Against Severe COVID-19 Was 100% $MRNA tweet at 6:59am: *MODERNA SET TO FILE FOR U.S., EU CLEARANCE FOR COVID-19 VACCINE tweet at 7:00am: *No Serious Safety Concerns Identified With Covid-19 Vaccine, Moderna Says $MRNA tweet at 7:00am: MODERNA EXPECTS U.S. FDA ADVISORY COMMITTEE MEETING TO BE SCHEDULED FOR DEC. 17 #News #Forex #USModerna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA). The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.